Affiliation:
1. Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China
2. School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen University, Shenzhen 518060, China
Abstract
Dysbiosis of the gut microbiota and metabolites is found in both pulmonary hypertension patients and pulmonary hypertension rodent models. However, the exact changes in gut microbiota during the development of pulmonary hypertension is unclear. The function of the gut microbiota is also ambiguous. Here, this study showed that the gut microbiota was disrupted in rats with hypoxia (Hyp)-, hypoxia/Sugen5416 (HySu)-, and monocrotaline (MCT)-induced pulmonary hypertension. The gut microbiota is dynamically changed during the development of Hyp-, HySu-, and MCT-induced rat pulmonary hypertension. The variation in the α diversity of the gut microbiota in Hyp-induced pulmonary hypertension rats was similar to that in rats with MCT-induced pulmonary hypertension and different from that in rats with HySu-induced pulmonary hypertension. In addition, six plasma biomarkers, His, Ala, Ser, ADMA, 2-hydroxybutyric acid, and cystathionine, were identified in Hyp-induced pulmonary hypertension rats. Furthermore, a disease-associated network connecting Streptococcus with Hyp-induced pulmonary hypertension-associated metabolites was described here, including trimethylamine N-oxide, Asp, Asn, Lys, His, Ser, Pro, and Ile.
Funder
Shenzhen-Hong Kong Collaborative Innovation Research
National Natural Science Foundation of China
Shenzhen Municipal Basic Research Program Grant
Guangdong Provincial Key Laboratory of Regional Immunity and Diseases
Subject
Virology,Microbiology (medical),Microbiology
Reference44 articles.
1. Macitentan and morbidity and mortality in pulmonary arterial hypertension;Pulido;N. Engl. J. Med.,2013
2. The prostacyclin pathway in pulmonary arterial hypertension: A clinical review;Expert Rev. Respir. Med.,2017
3. Endothelin receptor antagonists for pulmonary arterial hypertension;Liu;Cochrane Database Syst. Rev.,2009
4. Phosphodiesterase 5 inhibitors for pulmonary hypertension;Barnes;Cochrane Database Syst. Rev.,2019
5. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway;Beghetti;Pediatr. Pulmonol.,2019
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献